After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...